• Silence Therapeutics plc, of London, raised up to £5.7 million (US$7.2 million) through the issue of new ordinary shares at 0.5 pence per ordinary share to certain investors, and up to 100 million new ordinary shares through open offer at 0.5 pence per share, plus a convertible loan of £1 million. The price represents a discount of approximately 44 percent to the closing price on July 11. The firm also entered a £10 million equity finance facility with Darwin Strategic Ltd.